Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial.
BACKGROUND
In unstable coronary artery disease short term treatment with low molecular weight heparin in addition to aspirin has been shown to be effective.


OBJECTIVE
To assess the cost effectiveness of extended treatment with dalteparin in patients managed with a non-invasive treatment strategy.


METHODS
Prospective, randomised, multicentre study.


METHODS
58 centres in Sweden, Denmark, and Norway, of which 16 were interventional.


METHODS
After at least five days' treatment with open label dalteparin, 2267 patients were randomised to continue double blind treatment with either subcutaneous dalteparin twice daily or placebo for three months. The patients' use of health service resources was recorded prospectively.


METHODS
Death/myocardial infarction.


RESULTS
After one month into the double blind period there was a 47% relative reduction in death or myocardial infarction in the dalteparin group compared with the placebo group (p = 0.002). There was a non-significant mean cost difference, favouring the placebo group, of 849 Swedish crowns (SEK) per patient (equivalent to 58 pounds sterling). The incremental cost effectiveness ratio for giving dalteparin treatment for one month was SEK 30 300 (range -78 000 to 139 000) (2060 pounds sterling, range -5300 pounds sterling to pound 9400 pounds sterling) per avoided death or myocardial infarct. At three months, the decrease in death or myocardial infarction was not significant, precluding cost effectiveness analyses.


CONCLUSIONS
There is a marginal and non-significant increase in costs for one month of extended dalteparin treatment compared with placebo. Extended dalteparin treatment lowers the risk of death or myocardial infarction in patients with unstable coronary artery disease. While in many countries the resources for early intervention are limited, extended dalteparin treatment up to one month is a cost effective bridge to invasive intervention.
Janzon
M
M
Institution of Medicine and Care, Linköping University, Sweden. magnus.janzon@imv.liu.se
Levin
L-A
LA
Swahn
E
E
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000191:economics* / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D017985:Dalteparin / Q000191:economics* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization / Q000191:economics; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012680:Sensitivity and Specificity
D000925:Anticoagulants; D017985:Dalteparin